Travere Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Travere Therapeutics generated cash of -$280,021,000, which is less than the previous year. Cash used in financing activities reached the amount of $218,752,000 last year. Net change in cash is therefore -$3,512,000.
Cash Flow
| 2014 | -45.84M | -37.26M | 95.31M |
|---|---|---|---|
| 2015 | -554K | -80.60M | 100.76M |
| 2016 | -1.59M | 10.37M | -5.69M |
| 2017 | 7.40M | 45.60M | 5.44M |
| 2018 | -24.95M | -203.29M | 231.86M |
| 2019 | -58.21M | 19.86M | -2.07M |
| 2020 | -42.74M | -61.32M | 127.71M |
| 2021 | -14.79M | -137.62M | 231.68M |
| 2022 | -186.29M | -32.55M | 117.57M |
| 2023 | -280.02M | 55.77M | 218.75M |
TVTX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 61.68M | 165.75M | 84.77M | 62.43M | 102.87M | 99.39M | 41.00M | 37.80M | 18.20M | 5.99M |
Operating activities | ||||||||||
Net income | -376.33M | -278.48M | -180.09M | -169.43M | -146.42M | -102.67M | -59.73M | -47.90M | 117.23M | -110.93M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 38.53M | 33.07M | 26.61M | 24.57M | 20.40M | 18.66M | 17.80M | 16.13M | 13.39M | 5.40M |
Stock-based compensation expense | 44.24M | 38.14M | 29.56M | 23.61M | 21.10M | 0 | 26.87M | 29.10M | 25.9M | 15.90M |
| Deferred income tax benefit | 44.24M | 38.14M | 29.56M | 23.61M | 21.10M | 0 | 26.87M | 29.10M | 25.9M | 15.90M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -11.26M | -682K | -59K | 2.30M | -5.18M | 152K | 4.94M | -6.09M | -4.50M | -7.95M |
Inventories | -39.42M | -2.06M | -1.81M | -5.06M | -1.95M | -2.77M | -1.70M | -306K | -1.17M | -282.50K |
Accounts payable | 24.76M | 2.30M | 2.77M | -6.03M | 9.25M | -2.70M | 2.65M | 9.67M | 3.37M | 20.30M |
Cash generated by operating activities | -280.02M | -186.29M | -14.79M | -42.74M | -58.21M | -24.95M | 7.40M | -1.59M | -554K | -45.84M |
Investing activities | ||||||||||
Purchases Of Investments | -443.94M | -385.38M | -547.07M | -214.96M | -223.71M | -331.34M | -102.41M | -184.11M | -198.53M | -18.04M |
Investments In Property Plant And Equipment | -668K | -28.55M | -24.15M | -119.84M | -15.56M | -19.70M | -14.00M | -11.92M | -7.03M | -3.96M |
Acquisitions Net | 0 | 0 | 19.05M | 113.07M | 15.37M | -15M | -13.12M | -500K | -33.43M | -29.15M |
Cash generated by investing activities | 55.77M | -32.55M | -137.62M | -61.32M | 19.86M | -203.29M | 45.60M | 10.37M | -80.60M | -37.26M |
Financing activities | ||||||||||
Common Stock Issued | 191.19M | 19.54M | 239.88M | 137.46M | 1.61M | 15.89M | 11.73M | 10.02M | 149.48M | 40M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.25M |
Repayments of term debt | 0 | 95.04M | 0 | 0 | 0 | -40.20M | 0 | 0 | -45M | -31.28M |
Cash used in financing activities | 218.75M | 117.57M | 231.68M | 127.71M | -2.07M | 231.86M | 5.44M | -5.69M | 100.76M | 95.31M |
Net Change In Cash | -3.51M | -104.06M | 80.98M | 22.33M | -40.43M | 3.47M | 58.39M | 3.19M | 19.60M | 12.20M |
Cash at end of period | 58.17M | 61.68M | 165.75M | 84.77M | 62.43M | 102.87M | 99.39M | 41.00M | 37.80M | 18.20M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |